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Introduction
Human Cytomegalovirus (CMV) is a ubiquitous virus 
which is contracted either vertically and/or horizontal-
ly. Also, it can be transmitted through primary infection; 
re-infection or reactivation.1 The virus sometimes caus-
es minimal disability, allowing infected individuals to re-
main active in order to afford maximum opportunity of  
encountering susceptible contacts. It is excreted from 
multiple sites as such varying degrees of  intimacy can 
lead to transmission.2 The virus is incriminated as an op-
portunistic infection in many parts of  the world.1 Acute 
CMV disease occur in a small proportion of  infected 
individuals, and is restricted to settings where ability to 
mount cellular immune response is compromised, such 
as transplacental transmission during pregnancy leading 
to fetal damage and reactivation or primary infection
of  immunocompromised individuals. Transmission in-
fected bodily secretions; thus hygiene and virus shed-
ding patterns remain important determinants of  in the
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general population depends on direct contact with the 
transmission. 1 CMV infection during pregnancy is a 
major cause of  congenital infection worldwide 3 with 
an incidence of  0.2 – 2.2% of  live births.4 Up to 15% of  
such children have neurologic damage5,6 which includes 
impaired development, mental retardation, and neuro-
sensory hearing deficit.7 Fetal or neonatal death occurs in 
about 10% of  fetuses or newborns following intrauter-
ine CMV infection.7 About 80% of  adults in the world 
have antibody against CMV.8 Few pregnant women are 
routinely screened for CMV infections during pregnan-
cy.7 Routine serological screening of  pregnant women in 
Europe has helped their understanding of  CMV infec-
tions among pregnant women. High level screening in 
Belgium has yielded data on maternal-fetal transmission 
rates at gestation.9 The Italians used national serologic 
screening to develop and evaluate methods to diagnose 
maternal and fetal CMV infections including the CMV 
IgG avidity assay, and to test CMV immunoglobulin 
interventions.10,11 The French used serologic screening 
to evaluate the role of  maternal education on CMV and 
the role of  hygienic intervention to prevent maternal 
acquisition during pregnancy.12 Nigeria is grappling with 
inadequate funding in the health sector, and managing 
conditions such as congenital CMV disease is an issue, 
hence the need to investigate the IgG level with a view 
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Abstract
Background: Primary Cytomegalovirus (CMV) infection during pregnancy is a frequent and serious threat to the fetus. As 
there is no vaccine alternative measures are needed to prevent congenital CMV infection. 
Objective: This study determined CMV Immunoglobulin G (IgG) antibody among pregnant women in order to ascertain 
the immune status of  mothers to guide policy makers.
Methods: A semi-structured questionnaire was initially administered to obtain information on demographic details, stage of  
pregnancy and risk factors. Blood was collected by venipuncture from 180 women attending the antenatal clinic in Murtala 
Mohammed Specialist Hospital Kano, Kano State, Nigeria. Sera samples were screened using CMV IgG ELISA kit (Dialab, 
Austria).
Results: Out of  180 pregnant women, 164 (91.1%) were seropositive. Based on stages of  pregnancy 6/6(100%), 52/60(86.7%) 
and 106/114(93.0%) were seropositive among women in the first, second and third trimesters respectively. 
Conclusion: Seroprevalence of  pregnant women to CMV Ig G is high, hence the need for CMV - IgM screening to know 
the extent of  active infection. There is also need for public enlightenment on the methods of  transmission, effective preven-
tion and control strategies. 
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to guiding policy makers and educating pregnant moth-
ers on ways of  preventing infection to reduce birth of  
otherwise helpless children. 
Material and methods
Study area / population
Samples were collected from a cross-section of  preg-
nant women attending the antenatal clinic of  Mur-
tala Mohammed Specialist Hospital (MMSH) Kano, 
Kano State, Nigeria. Sample size was calculated using 
formula n=N/1+N(d)2 to get 361pregnant women, 
where N=population size,   d= level of  precision.13 
One hundred and eighty-one pregnant women were 
randomly selected from an average of  3700 pregnant 
women attending the antenatal clinic. Ethical approval 
was obtained from the MMSH Management Board and 
informed consent was sought and obtained before col-
lection of  the blood samples.
Sample collection and processing
About 5ml of  venous blood was collected from each 
patient using a 23gauge needle and syringe. The blood 
was transferred into a test tube and labeled properly 
with patient’s identification number. The blood sample 
was centrifuged at 3,000g for 5mins. The serum was ob-
tained using Pasteur pipette and transferred into clean 
cryovials and stored at –200C, until representative sam-
ples were obtained.
ELISA procedure
Qualitative determination of  CMV IgG antibodies 
was carried out using Enzyme Linked Immunosorb-
ent Assay (ELISA) technique using CMV IgG kit (Di-
alab®, Austria). Samples, reagents and calibrators were 
brought to room temperature before the test. Microw-
ell plate was labeled for sample, control and blank ap-
propriately. Samples were diluted 1:100 with the sample 
diluents. Afterwards 100µl of  each sample, positive and 
negative controls were dispensed into wells, leaving a 
well empty (blank). The plate was covered with adhe-
sive foil (VWR®, USA) and incubated at 37oC for 60 
minutes using an incubator (NAPCO, Thermo electron 
corporation). The adhesive foil was gently detached and 
plate washed seven times with 300µl diluted wash buff-
er (Biotek® plate washer). 100µl of  enzyme conjugate 
was then introduced into all wells, covered again and 
incubated at 37oC for another 60minutes. It was washed 
again seven times with 300µl diluted wash buffer. Then 
100µl of  the substrate was dispensed into all the wells 
including the blank. The plate was covered with a new 
adhesive and this time incubated at room temperature 
for 20min, protected from light after which 100µl of  
stop solution was finally introduced in all the wells. The 
absorbance of  each sample, control and blank were 
read using SoftMax Pro 5.4 software with Molecular 
devices® plate reader at a wavelength of  450nm. The 
cutoff  of  IgG was set at 0.5 World Health Organiza-
tion (WHO) IU/m. Samples with a concentration ≥0.5 
WHO IU/mL were considered positive for CMV IgG, 
while samples with a concentration below the cut off  
were considered as negative results. 
Statistical analysis
Statistical analysis of  results was done using the statisti-
cal package for social science (SPSS 16.0, IBM, USA). 
Pearson chi square test was used for the assessment and 
the differences were considered to be statistically sig-
nificant at P <0.05.
Results
Of  the 180 pregnant women screened, 164 (91.1%) 
had CMV IgG antibodies while 16 (8.9%) had none as 
shown in Table 1. 
Table 1. Distribution of  CMV IgG antibody in pregnant women by age group
___________________________________________________________________
Age group                  No. of  women                Seropositive (%)            Seronegative (%)
____________________________________________________________________
  17 – 20                          42                                  40 (95.2)                      2 (4.7)
21 – 24  24  18 (75.0) 6 (25.0)
25 – 28  52  48 (92.3) 4 (7.7)
29 – 32  38  38 (100) 0 (0.0)
  33 – 36                          24                                  20 (83.3)                      4 (16.7)
Total                               180                                164 (91.1)                     16 (8.9)
 __________________________________________________________________
African Health Sciences Vol 14 No.3 March 2014
126
There was no significant difference between the CMV 
IgG level within the age groups (P>0.05). Based on oc-
cupational status, the unemployed 120  had higher IgG 
level compared to the self  employed 38 and civil serv-
ants 6  in Table 2. 
Table 2. Distribution of  CMV IgG antibody by occupation and stage of  pregnancy
_____________________________________________________________________
Variable                         No. of  women                  Seropositive (%)        
_____________________________________________________________________
  Occupation 
Civil Servant 6 6 (100)
Self  employed 40 38 (95.0)
  Unemployed                134                                120 (89.5)  
  Stage of  pregnancy 
1st trimester 6 6 (100)
2nd trimester 40 52 (86.7)
  3rd trimester                114                                106 (93.0)                      
 ______________________________________________________________________
Based on stage of  pregnancy, Table 2 also shows 6 
women in the first trimester have IgG antibodies, in the 
second trimester 52 had antibodies 
CMV IgG antibody in the third trimester was highest 
106 (93.0%) while 8 (7.0%) were seronegative. Table 3 
shows that out of  the 168 women not transfused, 154 
(91.7%) had antibodies. 
Table 3. Distribution of  CMV IgG antibody according to blood transfusion status and parity
______________________________________________________________________
                                                                      No. of  women        Seropositive (%)     
______________________________________________________________________
Blood transfusion  Not transfused 168 154 (91.7)
Transfused 12 10 (83.3)




There was a significant difference between CMV IgG 
level among women who were not transfused and those 
who were (p<0.05). Out of  the12 women transfused, 
10 (83.3%) had antibodies. 
Based on parity (table 3) women with 1, 2, ≥5 numbers 
of  pregnancies had higher number of  people with IgG 
antibodies. Of  the 44 women with 3 - 4 pregnancies 40 
(24.4%) had IgG antibody.
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Discussion 
The gold standard for detecting maternal seroconver-
sion with regards to antibodies against CMV is sero-
logical diagnosis. The IgG assay is nearly 100% sensi-
tive and specific, readily available, and automated for 
high volume capacities.14,15 The high anti-CMV antibody 
of  91.1% observed among pregnant women in MMSH 
Kano is due primary infection and/or secondary in-
fection with intermittent excretion of  virus as a result 
of  reactivation of  an endogenous virus or exposure to 
new virus strain from exogenous sources. This is similar 
to a study among 5,959 pregnant women in Izmir Tur-
key 16 in which 98.3% IgG seropositivity was observed; 
179 pregnant women in Lagos southwest Nigeria where 
pregnant women had 97.2% anti-CMV IgG antibod-
ies.17 This is higher than the range of  60 – 70% in urban 
U.S. cities 18 but comparable to women of  childbearing 
age in Singapore, Thailand 9 and in Iran.19 Our findings 
in table 2 show that unemployed people had the high-
est CMV IgG seroprevalence of  89.5%. It was reported 
as early as 1973 that CMV antibodies was more preva-
lent in developing countries especially in areas of  lower 
socioeconomic conditions in comparison to developed 
countries.20
High seropositivity in 2nd and 3rd trimesters (Table 3) 
is in line with a report that recurrent infection occurs 
most frequently in the last two trimesters where marked 
transient depression of  CMV- specific cellular immu-
nity can be demonstrated.21 Although 83.3% seroposi-
tive pregnant women with history of  blood transfusion 
were identified in this study, high seropositivity has been 
extensively reported in transfusion-associated CMV.22,23 
Similarly, 96% anti-CMV IgG and 19.5% anti-CMV 
IgM seroprevalence was reported amongst apparently 
healthy blood donors in Lagos, Nigeria. This is quite 
significant because one out of  every four units of  blood 
donated is acutely infected by CMV.24 This study ob-
served high seroprevalence with increased parity (Table 
5). This finding is contrary to a study among pregnant 
women in London which reported high (88.2%) sero-
prevalence in first pregnancies among women.25 The 
high seroprevalence we observed could be due to reac-
tivation or re-infection with different strains of  CMV. 
Most Nigerian women have more than one child and 
love to be around children from other families even 
when they are pregnant, some shedding the virus, which 
underscores the problem of  silent viral infection during 
pregnancy. Currently, the American College of  Obste-
tricians and Gynecologists (ACOG) recommends that 
all women be educated about the ways that CMV infec-
tion may be acquired in pregnancy.26 They recommend 
careful handling of  potentially infected articles, such 
as diapers, and thorough hand washing when around 
young children or immunocompromised individuals. 
This is especially true for women who work in daycare 
settings and for those who are pregnant.27-33
Limitations of  this study
The sample size was halved because of  financial con-
straints. The authors preferred to detect anti-CMV IgG 
avidity to investigate recent acute infection and identify 
pregnant women at increased risk of  having infected fe-
tuses but could not due to financial constraints as well.
Conclusion
A significant proportion of  pregnant women in parts 
of  Kano metropolis are exposed to CMV infection. We 
recommend that health policies should include routine 
CMV-IgM screening or detection of  anti-CMV Ig G 
avidity for pregnant women, compulsory CMV anti-
body screening of  blood to be transfused to premature 
infants, pregnant women and immunocompromised in-
dividuals. 
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